Watch CBS News

Senator Pat Toomey Continues To Oppose The Iranian Nuclear Deal

PHILADELPHIA (CBS) -- Senator Pat Toomey continued his assault on the Iranian nuclear agreement and is holding out hope that the Senate can corral enough votes to override a Presidential veto when they reject the pact.

Toomey told Dom Giordano on Talk Radio 1210 WPHT that Iran will exploit the negotiations to continue developing a version of the bomb and also to fund terrorism.

"This does not block Iran's path to a nuclear. It paves Iran's path to a nuclear bomb. It releases over $100 Billion virtually upfront, almost immediately, with which Iran will be free to do anything it wants. We know Iran does. Iran funds some of the world's most lethal and horrendous terrorist organizations."

He stated he is concerned that too much of what is contained in the agreement remains a secret.

"The more you dig into this, the worse it gets. How about the fact that there's these two side agreements, these two side documents between the IAEA and Iran that, not only have I not seen it, as a member of Congress, [Secretary of State} John Kerry hasn't seen them? These are important documents that go to the heart of what Iran's past nuclear activity has been so that the IAEA will be able to determine what new developments they've been pursuing."

Toomey is holding out hope that enough Democrats will cross over to defeat the settlement.

"Some of the Democrats who are very supportive of the deal have been attempting to get a list of Democrats to publicly declare support for the deal and to have that list have enough names that they can prove that they have the votes to sustain a President's veto, if we send him a resolution of disapproval. They have not been able to get enough names to go on record in support of this deal. That doesn't tell me that we're going to be able to defeat it, but it tells me it's still possible."

View CBS News In
CBS News App Open
Chrome Safari Continue
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.